Patents by Inventor Concepcion Pedregal-Tercero

Concepcion Pedregal-Tercero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20120214784
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 23, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal Tercero, Miguel Angel Toledo Escribano
  • Spiropiperidine compounds as ORL-1 receptor antagonists
    Patent number: 8232289
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: July 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal-Tercero, Miguel Angel Toledo Escribano
  • Methods of Treatment Using a Prodrug of an Excitatory Amino Acid
    Publication number: 20120172422
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 5, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Kappa selective opioid receptor antagonist
    Patent number: 8173695
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, David Lee McKinzie, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID
    Publication number: 20110207672
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Methods of treatment using a prodrug of an excitatory amino acid
    Patent number: 7964632
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 21, 2011
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Ivan Collado Caño, Jaime Gonzalo Blanco-Urgoiti
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20110118251
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 10, 2010
    Publication date: May 19, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen BENITO COLLADO, Nuria DIAZ BUEZO, Alma Maria JIMENEZ-AGUADO, Celia LAFUENTE BLANCO, Maria Angeles MARTINEZ-GRAU, Concepcion PEDREGAL-TERCERO, Miguel Angel TOLEDO ESCRIBANO
  • KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST
    Publication number: 20100197669
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 5, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Nuria DIAZ BUEZO, Concepcion PEDREGAL-TERCERO, David Lee MCKINZIE, Charles Howard Mitch
  • PRODRUGS OF EXCITATORY AMINO ACIDS
    Publication number: 20100113579
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: January 15, 2010
    Publication date: May 6, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Kappa selective opioid receptor antagonist
    Patent number: 7709522
    Abstract: A selective kappa opioid receptor antagonist, (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, and anxiety and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: May 4, 2010
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST
    Publication number: 20090186873
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Application
    Filed: January 13, 2009
    Publication date: July 23, 2009
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20090023785
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Application
    Filed: July 8, 2008
    Publication date: January 22, 2009
    Inventors: Concepcion Pedregal-Tercero, Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • Prodrugs of excitatory amino acids
    Patent number: 7456221
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: November 25, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080255152
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 16, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charies Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • Opioid receptor antagonists
    Patent number: 7414132
    Abstract: A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3?, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Marta Garcia De La Torre, Nuria Diaz Buezo, Prabhakar Kondaji Jadhav, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • PRODRUGS OF EXCITATORY AMINO ACIDS
    Publication number: 20080182889
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: March 31, 2008
    Publication date: July 31, 2008
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Diaryl ethers as opioid receptor antagonist
    Patent number: 7381719
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: June 3, 2008
    Assignee: Eli Lilly and Company
    Inventors: Maria-Jesus Blanco-Pillado, Marta Garcia De La Torre, Nuria Diaz Buezo, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi
  • PRODRUGS OF EXCITATORY AMINO ACIDS
    Publication number: 20070265342
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: July 5, 2007
    Publication date: November 15, 2007
    Inventors: David Coffey, James Monn, Concepcion Pedregal-Tercero, Steven Pedersen
  • Opioid receptor antagonists
    Patent number: 7288543
    Abstract: A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3?, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: October 30, 2007
    Assignee: Eli Lilly and Company
    Inventors: Howard Barff Broughton, Nuria Diaz Buezo, Charles Howard Mitch, Concepcion Pedregal-Tercero